Background {#Sec1}
==========

Multidrug resistant clinical isolates have important clinical consequence in community and hospital settings \[[@CR1]\]. They have evolved as a global concern, exacerbated by under reporting in some regions of the world \[[@CR2]\]. The tendency of these isolates concurrently resistant to other groups of antibiotics significantly limits the selection of antibiotics for treatment of infections \[[@CR3]\]. The development of resistance for third generation cephalosporin is attributed to production of *β*-lactamases including extended-spectrum-*β*- lactamases (ESBLs), AmpCs and carbapenemases \[[@CR4]\]. The most significant *β*-lactamase genes are variants of CTX-M, SHV, TEM, VEB, GES, PER, TLA and OXA which have broadened the substrate specificity against ceftazidime, cefotaxime and ceftriaxone \[[@CR4], [@CR5]\]. These genes have broad host range but predominantly found in *Escherichia coli* and *Klebsiella* spp. \[[@CR6]\]. While, OXA genes are found predominantly in *Pseudomonas* spp. and *Acinetobacter* spp. \[[@CR7]\]. Moreover, many clinical pathogens harbor more than one *β*-lactam genes \[[@CR8]\]. Plasmid association of these genes makes them easily spreadable. Due to the diversity of these enzymes, multiplex-PCR based detection methods have become a widely used tool for epidemiological surveys \[[@CR8]--[@CR10]\].

Asian countries are highly affected by extended spectrum-*β*-lactamase-producers inducing multidrug-resistant phenotype \[[@CR11]--[@CR14]\]. Several studies have reported the community-association of ESBL-producers \[[@CR11], [@CR14], [@CR15]\]. In Pakistan, an increase in the number of ESBL-associated infections has been observed in last few decades \[[@CR16]--[@CR21]\]. Lack of regular surveillance programs at national or international levels, inadequate infection control agencies, lack of facilities and inappropriate diagnostic approaches contribute to the emergence of the antibiotic resistance in bacteria \[[@CR2], [@CR10], [@CR22]\]. Moreover, dissemination of these isolates in the community demands the urgent call for surveillance of resistance and molecular characterization for extended-spectrum-*β*-lactamase-producers \[[@CR23]\]. This study was designed to check molecular epidemiology of *bla*~*CTX−M*~*, bla*~*TEM*~*, bla*~*SHV*~ *and bla*~*OXA*~ genes among ESBL-producers in Pakistani population to have a generalized view about the situation in our region.

Materials and Methods {#Sec2}
=====================

Study design {#Sec3}
------------

This cross-sectional study was conducted at the Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore in collaboration with the Department of Pathology, Allama Iqbal Medical College/ Jinnah Hospital, Lahore, Punjab Institute of Cardiology (PIC), Lahore, Doctors hospital, Lahore and Citilab and Research center, Lahore from August 2014 to September 2017. This study was approved by the ethical review board of the Citilab and Research Center, Lahore under reference: 28*th*-18 CLRC/ 28*th*.

Bacterial Isolates {#Sec4}
------------------

A total of 2,372 samples were processed during study period; 77 % (*n*=1835) cultures were positive and 54 % (*n*=995) gram negative non-duplicate clinical isolates from various sources were collected by standard culturing methods. Antibiotic susceptibility testing (AST) was performed according to the guidelines provided by clinical laboratory standards institute \[[@CR24]\] by using standard antibiotic discs as mentioned in our previous study \[[@CR16]\]. Multiple- antibiotics resistance (MAR) value was calculated as reported before \[[@CR25]\]. *E*. coli ATCC 25922 was used as positive control and K. pneumoniae ATCC 700603 was used as negative control \[[@CR26]\]. Analytical profile index (API 20-E) was used for biochemical characterization of isolates resistant to third generation cephalosporins.

Phenotypic confirmation of ESBL-producers {#Sec5}
-----------------------------------------

Third generation cephalosporin resistant (3GC-R) isolates as screened by Antibiotic susceptibility test (AST) were subjected to: double disc synergism test (DDST), combination disc test (CDST) and epsilometric test (E-test) for confirmation of ESBL-production \[[@CR24]\]. In DDST, amoxicillin (AMC 20/10μg), cefuroxime (CRO 30μg), ceftazidime (CAZ 30μg) and cefotaxime (CTX 30μg) were applied \[[@CR27]\]**.** In CDST, CAZ (30μg) and CTX (30μg) alone and in combination with clavulanic acid (CTC (40μg) and CZC (40μg) were used \[[@CR16]\]. All discs used were from Oxoid, Inc (Canada). For E-test, CTX / CTX+ and CAZ/CAZ+ strips from AB BIODISK MICTM were used \[[@CR24]\].

Molecular detection {#Sec6}
-------------------

The DNA used for multiplex-PCR was extracted by the heat lysis method \[[@CR16]\]. In Multiplex-PCR, 2 μl whole cell lysate DNA for each isolate was used separately in 25 μl PCR-master mix and amplification primers as previously mentioned \[[@CR16], [@CR28], [@CR29]\]. PCR amplification conditions were: Initial step of denaturation at 95°C for 5 min followed by 35 cycles of denaturation at 95°C for 1 min then annealing at 56°C for 1.5 min, extension at 95°C for 1 min and the final extension was done at 95°C for 10 min (Table [1](#Tab1){ref-type="table"}).Table 1Primer sequences and amplification conditions used in this studyTarget genePrimer nameSequenceAnnealing temp (°C)Product size (bps)References*bla* ~CTXM-1~CTXM1-FGACGATGTCACTGGCTGAGC55500\[[@CR8]\]CTXM1-RAGCCGCCGACGCTAATACA*bla* ~CTXM-3~CTXM825FCGCTTTGCCATGTGCAGCACC55300\[[@CR8]\]CTXM825RGCTCAGTACGATCGAGCC*bla* ~SHV~SHV-FAGGATTGACTGCCTTTTTG56392\[[@CR9]\]SHV-RATTTGCTGATTTCGCTCG*bla* ~TEM~TEM-CATCAGCAATAAACCAGC56516\[[@CR9]\]TEM-HCCCCGAAGAACGTTTTC*bla* ~OXA~OXA-FATATCTCTACTGTTGCATCTCC56619\[[@CR9]\]OXA-RAAACCCTTCAAACCATCC

Amplicon sequencing and in-silico analysis {#Sec7}
------------------------------------------

PCR amplified products were sequenced by Advance Bioscience International, Pakistan in collaboration with 1st Base, Malaysia \[[@CR30]\]. Nucleotide sequence similarity searches were performed using the services of National Centre for Biotechnology Information (NCBI) (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). BLAST, CLUSTALX, and MEGA 7.0 software were used for sequence alignment of amplicon sequenced obtained with already submitted sequences of *bla*~*CTX−M*~*, bla*~*TEM*~, *bla*~*SHV*~ and *bla*~*OXA*~ in GenBank.

Statistical Analysis {#Sec8}
--------------------

All statistical analyses were performed using IBM-SPSS statistics 23. Bivariate analyses were performed using chi-square test for categorical variables. All *p*-values were two sided. The percentage values included in this article are the "valid percentages," which exclude the missing data.

Results {#Sec9}
=======

Demographic data and distribution of clinical isolates {#Sec10}
------------------------------------------------------

A total of 50 % (*n*=497/995) third generation cephalosporin resistant (3GC-R) clinical isolates were found among 995 gram-negative isolates. These include 65 % (*n*=321) *Escherichia coli*, 25 % (*n*=124) *Klebsiella pneumoniae,* 5 % (*n*=24) *Pseudomonas aeruginosa* and 4 % (*n*=20) were *Enterobacter* spp. and small number of *Acinetobacter* spp. 2 % (*n*=8) were found. These isolates were obtained from urine 59 % (*n*=278), pus 20 % (*n*=99), wound swab 6 % (*n*=29), Foley's tip 3 % (*n*=17), sputum 3 % (*n*=16), tracheal secretion 3 % (*n*=14), body fluids 2 % (*n*=10), blood 8 % (*n*=40) and HVS 1 % (*n*=4) respectively with *p*-value \<0.0001. Among study population, significantly (*p*-value \<0.0001) higher number of strains were isolated from males 53 % (*n*=265) compared to females 47 % (*n*=232). Age group 41-60 years was prevalent 35 % (*n*=174) followed by 21-40 years 29 % (*n*=146) (*p*-value \<0.0001) (Table [2](#Tab2){ref-type="table"}).Table 2Distribution of isolates according to different parameters from 2014 to 2017Study year20142015201620172014--2017Chi-score*p-*valueParametersInitial screening Samples Processed400 (22)500 (27)500 (27)435 (24)1835 (48)9.330.0023 Strains Screened230 (23)230 (29)230 (23)250 (25)995 (54)1.910.1671 3GC-R^a^134 (27)85 (23)85 (17)166 (33)497 (50)30.05\<0.0001Third generation cephalosporin resistant isolates *Klebsiella* spp.22 (18)32 (26)45 (36)25 (20)124 (25)31.19\<0.0001 *Escherichia coli*106 (33)41 (13)40 (12)134 (42)321 (65)21.990.0012 *Enterobacter* spp.6 (30)12 (60)0 (0)2 (10)20 (4)15.950.0140 *Pseudomonas* spp.0 (0)24 (100)0 (0)0 (0)24 (5)74.48\<0.0001 *Acinetobacter* spp.0 (0)3 (38)0 (0)5 (63)8 (2)4.320.6335Demographic Data Gender based distribution  Male69 (51)47 (42)47 (55)102 (61)265 (53)11.520.0342  Female65 (49)65 (58)38 (45)64 (39)232 (47) Age wise distribution  \< 1--2017 (25)27 (20)14 (21)10 (15)68 (14)32.190.0013  21--4033 (23)26 (19)40 (27)47 (32)146 (29)60.29\<0.0001  41--6045 (26)41 (31)27 (16)61 (35)174 (35)58.53\<0.0001  61--8039 (37)15 (11)4 (4)47 (45)105 (21)53.13\<0.0001  \> 800 (0)3 (2)0 (0)1 (25)4 (1)7.980.7867 Sample source  Urine80 (58)150 (66)26 (31)16 (33)272 (55)18.930.0003  Blood5 (4)11 (5)5 (6)12 (25)33 (7)27.4\<0.0001  Pus40 (29)33 (15)18 (21)7 (15)98 (20)9.740.0209  Wound2 (1)17 (8)11 (13)13 (27)43 (9)29.26\<0.0001  Tissue2 (1)0 (0)1 (1)0 (0)3 (1)3.750.2898  Sputum3 (2)1 (0)12 (14)0 (0)16 (3)38.79\<0.0001  Tips1 (1)0 (0)2 (2)0 (0)3 (1)60.1116  Secretions0 (0)4 (2)8 (9)0 (0)12 (2)22.12\<0.0001  Fluid3 (2)7 (3)0 (0)0 (0)10 (2)4.020.2540  High vaginal swab2 (1)2 (1)2 (2)0 (0)6 (1)1.770.6215  Washings0 (0)1 (0)0 (0)0 (0)1 (0)1.20.731Phenotypic detection tests Phenotypic test  AST^b^134 (27)112 (23)85 (17)166 (33)497 (50)1.450.9975  CDST^c^102 (26)65 (16)85 (21)147 (37)399 (80)20.80.0136  DDST^d^95 (35)89 (33)18 (7)71 (26)273 (55)32.190.0002  E-test^e^74 (24)84 (28)37 (12)108 (36)303 (61)5.360.8019Percentages are mentioned in parenthesis^a^Third generation cephalosporin resistant^b^Antibiotic susceptibility testing^c^Combination disc test^d^Double disc synergy test^e^Epsilometric test

Phenotypic screening and confirmation of ESBL-producers {#Sec11}
-------------------------------------------------------

Isolates had high resistance towards *β*-lactams including cefotaxime and cefaclor 100% (*n* = 497). While 98.6% (*n* = 490) and 96.4% (*n* = 479) isolates were resistant for cefuroxime and ceftazidime respectively. While, resistance for carbapenems was low 11% (*n* = 55). Moderate to high resistance towards aminoglycosides (67--89%) and quinolones (74--82%) was seen except amikacin 14% (*n* = 70). While isolates were quite susceptible to cefoparazone/sulbactam 6% (*n* = 30) and piperacillin/tazobactam 24% (*n* = 119). 60% (*n* = 303) of isolates had MAR-value in the range of 0.60 to 0.799, while 27% (*n* = 136) were having MAR-value of 0.8--1.0. Rest of the isolates 14% (*n* = 57) had MAR-value of 0.2--0.59. ESBL-positivity was as follows; double disc synergy test 55% (*n* = 273), combination disc test 79% (*n* = 392) and epsilometric-test showed 58% (*n* = 288). Year-wise data indicated frequency of ESBL-producers among 3GC-R has increased from 76% (*n* = 102) to 88% (*n* = 146) during study years (Table [2](#Tab2){ref-type="table"}). *E. coli* 75% (*n* = 241), *K. pneumoniae* 80% (*n* = 99), *Pseudomonas* spp. 72% (*n* = 15) and *Enterobacter* spp. 75% (*n* = 15) had ceftazidime/ceftazidime+ MIC \> 32/0.064 = 500 while 5.6% (*n* = 28) remained non-determined. Cefotaxime/cefotaxime+ \> 16/0.016 = 1000 was most frequent MIC with *E. coli 64*% (*n* = 206), *K. pneumoniae 69*% (*n* = 85), *Pseudomonas spp.* 63% (*n* = 15), while 6% (*n* = 30) remained non-determined by cefotaxime/cefotaxime+ (Table [3](#Tab3){ref-type="table"}).Table 3Minimum Inhibitory Concentration (MIC) of applied antibiotics along with clavulanic acidCeftazidime/ceftazidime with clavulanic acid MIC^a^ (μg/ml)MIC ratio\> 32/\> 4 (ND)^a^\> 32/0.064 = 500\> 32/0.125 = 25624/0.19 = 12616/0.38 = 42.14/0.25 = 16*E. coli* (*n* = 321)13 (4%)241 (75%)39 (12%)19 (6%)3 (1%)6 (2%)*Klebsiella spp.* (*n* = 124)2 (1.8%)99 (80%)10 (8.3%)6 (4.6%)7 (5.5%)0 (0%)*Pseudomonas spp.* (*n* = 24)5 (21%)17 (72%)2 (8.3%)0 (0%)0 (0%)0 (0%)*Enterobacter spp.* (*n* = 20)2 (10%)15 (75%)2 (10%)0 (0%)1 (5%)0 (0%)*Acinetobacter spp.* (*n* = 8)6 (75%)2 (25%)0 (0%)0 (0%)0 (0%)0 (0%)Cefotaxime/cefotaxime with clavulanic acid MIC (μg/ml)MIC ratio\> 16/\> 1 (ND)^b^\> 16/0.016 = 100012/0.023 = 5213/0.023 = 1308/0.125 = 644/0.094 = 42.5*E. coli* (*n* = 321)17 (5.4%)206 (64%)58 (18%)17 (5.4%)12 (3.7%)11 (3.4%)*Klebsiella spp.* (*n* = 124)2 (1.8%)85 (69%)19 (15%)9 (7.4%)7 (5.5%)2 (1.8%)*Pseudomonas spp.* (*n* = 24)2 (8.3%)15 (63%)0 (0%)0 (0%)2 (8.3%)1 (4%)*Enterobacter spp.* (*n* = 20)1 (5%)2 (10%)0 (0%)0 (0%)0 (0%)17 (85%)*Acinetobacter spp.* (*n* = *8)*8 (100%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)^a^Minimum-inhibitory concentration and ^b^Not-determined

Association analysis indicated among 82% (*n* = 262) ESBL-positive *E. coli*, females were more prone to such infection with 53% (*n* = 138). While, infectivity rate was high for males with ESBL-positive *Klebsiella pneumoniae* 54% (*n* = 47) and *Enterobacter* spp. 57% (*n* = 8) (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). High frequency of ESBL-producers 36% (*n* = 140) came from age group of 41--60 years. Age associated ESBL-infectivity rate was more confined to age group 41--60 years in *E. coli* 36% (*n* = 94), *Klebsiella* spp. 38% (*n* = 35) and *Pseudomonas* spp. 33% (*n* = 8) (Table [6](#Tab6){ref-type="table"}). Urine samples were frequent source of ESBL-phenotype among *E. coli* 65% (*n* = 171), *Klebsiella* spp. 39% (*n* = 35) and *Pseudomonas* spp. 38% (*n* = 9) (Table [5](#Tab5){ref-type="table"}).Table 4Gender based association of infectivity among different isolatesIsolatesGenderNumber (%)ESBL-productionChi-scoreOdds ratio*p*-valuePositive (%)Negative (%)*E. coli* (*n* = 321)Male152 (47)124 (82)28 (18)1.8349961.0317 (0.5834--1.8245)0.9146Female169 (53)138 (82)31 (18)*Klebsiella spp.* (*n* = 124)Male68 (55)49 (72)19 (28)4.081240.989 (0.4502--2.1746)0.919Female56 (45)40 (71)16 (29)*Pseudomonas spp.*(*n* = 24)Male13 (54)10 (77)3 (23)0.9940830.3333 (0.0294--3.775)0.375Female11 (46)10 (91)1 (9)*Enterobacter spp.*(*n* = 20)Male12 (60)8 (67)4 (33)1.1236260.6667(0.0902--4.9281)0.6912Female8 (40)6 (75)2 (25)*Acinetobacter spp.* (*n* = 8)Male3 (38)2 (67)1 (23)0.3379120.4000 (0.0160--10.0173)0.5771Female5 (62)5 (100)0 (0)Table 5Age-wise association of ESBL-production with different isolatesIsolatesAge groupNumber (%)ESBL-productionChi-score*\*p*-valuePositive (%)Negative (%)*Escherichia coli* (*n* = 321)0--2044 (14)41 (93)3 (7)0.90067821--40100 (31)82 (82)18 (3)0.76744241--60120 (37)94 (78)26 (3)0.04574661--8053 (17)45 (85)8 (6)1.40471\> 804 (1)0 (0)4 (75)14.33333\<0.0001*Klebsiella* spp. (*n* = 124)0--2022 (18)18 (82)4 (18)0.17054321--4038 (31)28 (74)10 (26)0.45063241--6046 (37)35 (76)11 (24)0.11834361--8017 (14)10 (59)7 (41)3.734724\> 811 (1)1 (100)0 (0)0.27907*Pseudomonas* spp. (*n* = 24)0--206 (25)5 (83)1 (17)0.09334621--405 (21)4 (80)1 (20)0.0096941--6010 (42)8 (80)2 (20)0.0193861--803 (13)3 (100)0 (0)0.837209\> 810 (0)0 (0)0 (0)*Enterobacter* spp. (*n* = 20)0--205 (25)4 (80)1 (25)0.0096921--405 (25)3 (60)2 (67)0.96899241--605 (25)2 (40)3 (150)4.2732560.0461--805 (25)5 (100)0 (0)1.395349\> 810 (0)0 (0)0 (0)*Acinetobacter spp.* (*n* = 8)0--201 (13)0 (0)1 (13)3.5833330.0321--403 (38)1 (13)2 (25)3.5374680.0341--601 (13)1 (13)0 (0)0.2790761--802 (25)1 (13)1 (13)0.931202\> 811 (13)1 (13)0 (0)0.27907\*only *p*-values \<0.05 are shownTable 6Association of ESBL-production with type of isolates under investigationIsolatesTotal number (%)ESBL-productionChi-score*p*-valuePositive (%)Negative (%)*Escherichia coli*321 (65)262 (82)59 (18)6.792369985.00951*Klebsiella spp.*124 (25)89 (72)35 (28)*Pseudomonas spp.*24 (5)20 (83)4 (17)*Enterobacter spp.*20 (4)14 (70)6 (30)*Acinetobacter spp.*8 (2)7 (88)1 (13)

Molecular detection {#Sec12}
-------------------

After screening, ESBL-producing isolates (*n* = 392) as detected by combination disc test were processed for the detection of *bla*~*CTX − M*~*, bla*~*SHV*~, *bla*~*TEM*~ and *bla*~*OXA*~ encoding genes by PCR. In Singleplex-PCR, *bla*~*CTX − M*~ genes were predominant 76% (*n* = 303) followed by *bla*~*OXA*~ 52% (*n* = 203), *bla*~*TEM*~ 28% (*n* = 109) and *bla*~*SHV*~ 21% (*n* = 82). Multiplex-PCR showed that *bla*~*CTX − M//SHV/TEM/OXA*~ and *bla*~*OXA/TEM/SHV*~ gene combination was present in 9% (*n* = 36) and 11% (*n* = 43) respectively. *bla*~*TEM/SHV*~ and *bla*~*TEM/OXA*~ combination was present in 13% (*n* = 51) and 27% (*n* = 105) respectively (Table [7](#Tab7){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}).Table 7Association of ESBL-production with type of specimenSample (*N* = 497)Number (%)ESBL-productionChi-score*p*-valuePositive (%)Negative (%)Urine271 (55)221 (82)50 (18)19.50840541\<0.0001Pus97 (20)73 (75)24 (25)Wound Swab39 (8)33 (85)6 (15)Fluids and secretions24 (5)16 (67)8 (33)Catheters and tips17 (3)11 (65)6 (35)Blood18 (4)10 (56)8 (44)Sputum16 (3)16 (100)0 (0)High Vaginal Swab7 (2)6 (88)1 (12)Others6 (1)6 (100)0 (0)Table 8Gene variants obtained by amplicon sequencing in different isolatesGene variantTotal (*n* = 392)*Escherichia coli* (*n* = 321)*Klebsiella pneumoniae* (*n* = 124)*Enterobacter cloacae* (*n* = 20)*Pseudomonas aeruginosa* (*n* = 24)*Acinetobacter baumannii* (*n* = 8)Chi-score*\*p*-value*bla* ~CTXM-1~303 (76)238 (74)53 (43)5 (25)7 (29)0 (0)13.2333292\< 0.0001*bla* ~CTX-M-15~260 (86)204 (98)48 (91)3 (50)5 (71)0 (0)6.3369670460.0118*bla* ~OXA~203 (52)126 (39)35 (28)15 (75)19 (79)8 (100)11.31364661\<0.0001*bla* ~OXA-1~99 (49)69 (55)0 (0)7 (50)0 (0)0 (0)4.8006122790.0284*bla* ~OXA-50~7 (3)0 (0)0 (0)0 (0)7 (100)0 (0)3.9977403940.0456*bla* ~OXA-144~2 (1)0 (0)0 (0)0 (0)0 (0)2 (25)32.84026642\<0.0001*bla* ~OXA-23~4 (2)0 (0)0 (0)0 (0)0 (0)4 (50)65.68053525\<0.0001*bla* ~OXA-371~2 (1)0 (0)0 (0)0 (0)0 (0)2 (25)32.84026642\<0.0001*bla* ~OXA-58~2 (1)0 (0)0 (0)0 (0)0 (0)2 (25)32.84026642\<0.0001*bla* ~OXA-68~2 (1)0 (0)0 (0)0 (0)0 (0)2 (25)32.84026642\<0.0001*bla* ~OXA-94~2 (1)0 (0)0 (0)0 (0)0 (0)2 (25)32.84026642\<0.0001*bla* ~TEM~109 (28)82 (29)23 (19)4 (20)0 (0)0 (0)16.56736583\<0.0001*bla* ~TEM-1B~69 (34)76 (33)19 (83)1 (25)0 (0)0 (0)1.942065018*bla* ~SHV~82 (21)10 (3)65 (52)7 (35)0 (0)0 (0)13.56652163\<0.0001*bla* ~SHV-10~5 (6)1 (10)4 (8)0 (0)0 (0)0 (0)5.5664568980.0183*bla* ~SHV-11~47 (57)0 (0)47 (89)0 (0)0 (0)0 (0)22.26584202\<0.0001*bla* ~SHV-1~13 (16)0 (0)13 (25)0 (0)0 (0)0 (0)16.69937791\<0.0001*bla* ~SHV-27~4 (5)0 (0)4 (8)0 (0)0 (0)0 (0)5.5664568980.0183*bla* ~SHV-28~4 (5)0 (0)4 (8)0 (0)0 (0)0 (0)5.5664568980.0183*bla* ~SHV-83~24 (29)0 (0)24 (45)0 (0)0 (0)0 (0)5.5664568980.0183Gene combinations *bla*~CTX-M-15~ + *bla*~OXA-1~71 (14)55 (60)5 (42)2 (10)0 (0)0 (0)5.440653310.0197 *bla*~OXA-1~ + *bla*~TEM-1B~30 (6)22 (20)6 (50)1 (5)0 (0)1 (13)0.485769791 *bla*~CTX-M-15~ + *bla*~TEM-1B~44 (9)33 (7)10 (8)0 (0)0 (0)1 (13)1.009389671 *bla*~CTX-M-15~ *+ bla*~SHV-11~4 (3)0 (0)4 (33)0 (0)0 (0)0 (0)19.46666667\<0.0001 *bla*~CTXM-15~ + *bla*~OXA-1~ + *bla*~TEM-1B~28 (4)22 (7)5 (4)0 (0)0 (0)1 (25)0.234071093\*only *p*-values \<0.05 are shownFig. 1Year-wide prevalence of ESBL-encoding genes among clinical isolates. Percentages of ESBL-genes detected every year is tabulated

Amplicon sequencing and subsequent analysis indicated *bla*~*CTX − M −* 15~ 86% (*n* = 260) was prevalent among *bla*~*CTX − M −* 1~ group. *bla*~*OXA −* 1~ 49% (*n* = 99) were found among *bla*~*OXA*~ amplicons and *bla*~*TEM −* 1*B*~ 63% (*n* = 69). 83% (*n* = 190) of *E. coli had bla*~*CTX − M −* 15~ followed by *bla*~*OXA −* 1~ 55% (*n* = 69) and *bla*~*TEM −* 1*B*~ 33% (*n* = 76). *Klebsiella spp.* contained *bla*~*CTX − M −* 15~ 67% (*n* = 36) followed by *bla*~*SHV −* 11~ 89% (*n* = 47) and bla~TEM *−* 1*B*~ 34% (*n* = 19). While, *Pseudomonas spp.* and *Acinetobacter baumannii* had variants of OXA (*bla*~*OXA −* 50~, *bla*~*OXA −* 144~, *bla*~*OXA −* 23~, *bla*~*OXA −* 371~, *bla*~*OXA −* 58~, *bla*~*OXA −* 68~ and *bla*~*OXA −* 94~) (Table [8](#Tab8){ref-type="table"}).

Discussion {#Sec13}
==========

Extensive use of antibiotics has resulted in resistance against variety of antibiotics including cephalosporins. They affect countries all over the world but control and prevention of ESBL-producers is severely compromised in underdeveloped countries \[[@CR31]--[@CR33]\].

Here, high prevalence of third generation cephalosporin resistant isolates (50%) was observed which has subsequently increased by 1.13-fold from 2014 to 2017. This high resistance also indicates high selection pressure for third generation cephalosporin resistant isolates \[[@CR34]\]. This increase of resistance is worrisome as we are left with few treatment options including cephalosporins. Widespread usage of antibiotics might be the factor of such increase in resistance in our hospital settings \[[@CR16], [@CR35]\].

*E. coli* had high 3GC-R burden compared to *Klebsiella* spp. and *Enterobacter* spp. Bari et al., reported similar findings in a study conducted in 2013 in Lady Reading Hospital Peshawar \[[@CR36]\]. These results are comparable to findings in Tanzania where 45% ESBL-producers have been reported \[[@CR37]\]. Similar findings from different regions of the world were observed as previously studied \[[@CR38], [@CR39]\]. Nahid et al., reported very high prevalence of ESBL-producers (87.5%) but this is because she worked on Metallo-*β*-lactamase producers which are highly resistant organisms \[[@CR40]\].

ESBL infectivity rate in males was moderately high as compared to females. This rate is quite similar to the rate reported by Afirdi et al. \[[@CR41]\]. In our study ESBL infections were significantly higher in the mean age group of 41-60 years whereas, high infection rates have been reported in old age individuals who are immuno-compromised and hence, more prone to infections \[[@CR42]\]. We have found isolates originating from females were more frequent ESBL-producers. According to many reports males have significantly higher rates of hospital-acquired infection and community-acquired infections are more prevalent in females \[[@CR42]--[@CR46]\]. These findings represent that males are more often exposed to the hospital settings compared to the females.

Studies indicated prevalence of ESBL-producers is variable in different regions of world as detected by phenotypic detection tests \[[@CR47]--[@CR50]\]. DDST determined only 54 % strains as ESBL-producers while CDST determined 79 % as ESBL-producers. Ejaz et al., reported similar detection efficiency of CDST as we reported here \[[@CR17]\]. Prevalence of ESBL-producing isolates is quite higher than from other parts of the world including India (42.3 %), Bangladesh (37.8 %). Dalela et al., reported 90 % sensitivity of CDST for the detection of ESBL-producers \[[@CR51]\]. E-test revealed that 61 % strains were ESBL-producers while 39 % remained non-determined by this technique. Mohanty et al. also reported 61 % positivity rate for ESBL-producers by E-test technique \[[@CR52]\]. Such discrepancies between susceptibility data and phenotypic test results have increased the demand for more sensitive methods of ESBL-producer detection for implementation into routine susceptibility testing procedures.Despite of high resistance burden of ESBL-producers, the usage of molecular detection methods is not very common. A recent meta-analysis describes only 11% studies that reported PCR-based detection methods for screening of ESBL-producers in Pakistan \[[@CR20]\]. Lack of knowledge and technical staff triggers the use of PCR-based methods as it is the rapid and reliable method of ESBL-producer detection \[[@CR8]\]. It seems that *bla*~*CTX − M*~ is predominant genotype in this region of the world. Another study from Pakistan indicated 72% of isolates had *bla*~*CTXM −* 15~ gene which was lower than prevalence of *bla*~*CTX-M*~ gene found in this study \[[@CR16]\]. Few studies from other parts of world have shown different prevalence of *bla*~*CTX-M*~ gene among isolates including 84.7% (Chile), 98.8% (China) and 13.6% (Tanzania) \[[@CR53]--[@CR55]\]. We observed *bla*~*TEM*~ and *bla*~*OXA*~ genes were less common in our settings with 50% prevalence. Report from Hamad Medical Corporation, Qatar stated that CTX-M group has evolved through mutations in *bla*~*TEM*~ and *bla*~*SHV*~ genes and is recent endemic \[[@CR56]\].

\-*Acinetobacter baumannii* isolates had OXA variants (*bla*~*OXA −* 23*,*58~ and others) which are carbapenemase-encoding genes \[[@CR57]\]. These variants have previously been isolated from France, Spain and Turkey which indicates the global spread \[[@CR50]\]. *bla*~*OXA −* 23~ was amplified from pan-drug resistance *A. baumannii* only which is in accordance with our results \[[@CR58]\]. But these *Acinetobacter baumannii* isolates did not carry any of the ESBL-encoding genes which terminate the co-existence of carbapenemase and ESBL-encoding genes. This is in accordance with already published article which states no significant relation between both groups \[[@CR59]\]. Appearance of different variants might provide extra advantage for these isolates to spread them and complicate the therapeutics.

With the passage of time increase in co-resistance of different ESBL-producing genes is worrisome as co-existence of multiple genes hinders the detection of ESBL-producers and complicates the treatment strategy for clinicians. Moreover, high plasmid burden was found these plasmids are involved in gene-transfer and they also carry additional antibiotic resistance genes along with *β*-lactam antibiotics.

Conclusions and Recommendations {#Sec14}
===============================

In conclusion, *bla*~CTX−M~-type ESBL-producing genes and *bla*~OXA~-type narrow spectrum-β-lactamases are prevalent among the isolates in our health care settings. Isolates had high resistance towards cephalosporins. Resistance towards cephalosporins and carbapenems has increased many folds during study period. Co-expression of multiple genes complicates the treatment strategy. *bla*~*CTXM−*15~, a pandemic genotype is quite prevalent and their plasmid association is a big thread for the community. There is a dire need for efficient molecular diagnostic tools for the detection of *bla* genes at laboratory level.

CDST

:   Combination disc test

DDST

:   Double disc synergy test

ESBL

:   Extended-spectrum *β*-lactamases

ESBLs

:   Extended-spectrum-β-lactamase-producing strains

E-Test

:   Epsilometric test

MAR

:   Multiple- antibiotics resistance

MIC

:   Minimum inhibitory concentration
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